Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN)

Lantern Pharma (NASDAQ:LTRN) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Lantern Pharma and Dyne Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$15.96 million	($1.78)	-2.06
Dyne Therapeutics	N/A	N/A	-$235.94 million	($3.35)	-3.70

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Lantern Pharma and Dyne Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	0	1	0	0	2.00
Dyne Therapeutics	0	1	11	2	3.07

Dyne Therapeutics has a consensus price target of $48.75, indicating a potential upside of 293.15%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Lantern Pharma.

Profitability

This table compares Lantern Pharma and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-56.91%	-51.17%
Dyne Therapeutics	N/A	-57.46%	-51.62%

Insider and Institutional Ownership

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Lantern Pharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

About Lantern Pharma

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.